Publications by authors named "M PALAFOX"
A novel Ce(III) complex with the triazole ligand 2b, which presents four H-bonded sites with amino acids of the MMP-2 receptor, was synthesized. The experimental IR and Raman spectra of this Ce(III) complex were well-interpreted based on their comparison to the theoretical scaled spectra using the scaling equations determined by two procedures and four density functional theory (DFT) levels. Therefore, the structure predicted for the synthesized Ce(III) complex was clearly characterized and confirmed.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the role of BRCA promoter methylation in triple-negative breast cancer (TNBC), emphasizing its potential as an alternative to rare somatic BRCA mutations, particularly in relation to the effectiveness of PARP inhibitors.
- Researchers analyzed BRCA promoter methylation in breast cancer metastases using advanced methylation profiling and tested tumor organoids derived from these tumors for their response to PARP inhibitors.
- The findings suggest that while BRCA promoter hypermethylation is rare in metastatic breast cancer, it is preserved in xenograft models and may serve as a valuable indicator for targeted PARP inhibitor therapy.
Article Synopsis
- The study focuses on a newly synthesized anticancer drug based on a 1,2,3-triazole structure, specifically 2-(4-chlorophenyl)-5-(pyrrolidin-1-yl)-2-1,2,3-triazole-4-carboxylic acid.
- Quantum chemical methods were employed to analyze and optimize the drug's molecular structure, confirming its characteristics through theoretical calculations and experimental data like IR and Raman spectroscopy.
- Additionally, molecular docking studies indicated how this drug interacts with specific amino acids in the MMP-2 receptor, highlighting the importance of triazole compounds in forming hydrogen bonds.
Article Synopsis
- The research focused on CDK4/6 inhibitors, specifically exploring how cellular senescence affects tumor growth in humans and its implications for cancer treatment.
- A phase II clinical trial involving 30 patients with dedifferentiated liposarcoma tested the CDK4/6 inhibitor abemaciclib, demonstrating a median progression-free survival of 33 weeks and a good safety profile.
- The study identified ANGPTL4 as a key factor in cell senescence, highlighting its role in immune response and suggesting that combining senolytics with abemaciclib could enhance treatment effectiveness in certain patients.
A structural and spectroscopic study of 5-chloroorotic acid (5-ClOA) biomolecule was carried out by IR and FT-Raman and the results obtained were compared to those achieved in 5-fluoroorotic acid and 5-aminoorotic acid compounds. The structures of all possible tautomeric forms were determined using DFT and MP2 methods. To know the tautomer form present in the solid state, the crystal unit cell was optimized through dimer and tetramer forms in several tautomeric forms.
View Article and Find Full Text PDF